Global Soliris (Eculizumab) Market Growth 2026-2032
The global Soliris (Eculizumab) market size is predicted to grow from US$ 1822 million in 2025 to US$ 1215 million in 2032; it is expected to grow at a CAGR of -3.4% from 2026 to 2032.
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.In 2025, global Soliris (Eculizumab) production reached approximately 339 k units.The average gross profit margin of this product is 65%.
The core opportunity for Soliris lies in the expanding clinical value of complement biology across rare diseases, autoimmune disorders, neuroimmunology, and kidney diseases. As physicians gain a deeper understanding of complement-mediated mechanisms, high-risk patients once scattered across hematology, nephrology, neurology, and intensive care are being identified earlier, supporting the expansion of targeted complement therapy from classic rare indications into broader immune-inflammatory settings. Corporate annual reports and regulatory documents show that Soliris has become a key benchmark for the commercialization of complement inhibitors. Its value is not limited to product revenue, but also extends to rare disease care pathways, patient screening, long-term treatment management, and global market access capabilities. For CEOs, marketing leaders, and investors, eculizumab represents an innovative biologics segment where high barriers, strong clinical value, and substantial willingness to pay coexist.The main challenges come from reimbursement pressure, competitive innovation, biosimilar entry, and safety management. As a high-value rare disease therapy, Soliris faces commercial constraints related to treatment cost and reimbursement access. At the same time, long-acting C5 inhibitors, subcutaneous complement drugs, alternative pathway inhibitors, and biosimilars are reshaping the competitive landscape. Clinically, complement inhibition requires strict management of risks such as meningococcal infection, meaning patients often require vaccination, risk education, and continuous monitoring. Because the target diseases involve limited patient populations, complex diagnostic pathways, and high demand for multidisciplinary collaboration, companies must continue investing in medical education, patient identification, real-world evidence, and payer communication to sustain lifecycle value.Downstream demand is shifting from rescue treatment for critically ill patients toward early diagnosis, early treatment, and long-term disease control. Hematology, nephrology, neurology, pediatrics, rheumatology, immunology, and rare disease centers now evaluate eculizumab not only through efficacy, but also through patient stratification, disease progression management, quality-of-life improvement, and long-term safety. As rare disease networks, genetic testing, complement testing, and multidisciplinary consultation systems mature, more potential patients may enter standardized treatment pathways. At the same time, patients and payers are placing greater emphasis on dosing convenience, treatment continuity, real-world benefit, and total healthcare cost control, encouraging companies to build a more complete ecosystem around drugs, diagnostics, follow-up, patient support, and access solutions.
LP Information, Inc. (LPI) ' newest research report, the ?Soliris (Eculizumab) Industry Forecast? looks at past sales and reviews total world Soliris (Eculizumab) sales in 2025, providing a comprehensive analysis by region and market sector of projected Soliris (Eculizumab) sales for 2026 through 2032. With Soliris (Eculizumab) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Soliris (Eculizumab) industry.
This Insight Report provides a comprehensive analysis of the global Soliris (Eculizumab) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Soliris (Eculizumab) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Soliris (Eculizumab) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Soliris (Eculizumab) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Soliris (Eculizumab).
This report presents a comprehensive overview, market shares, and growth opportunities of Soliris (Eculizumab) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Soliris (Eculizumab) market?
What factors are driving Soliris (Eculizumab) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Soliris (Eculizumab) market opportunities vary by end market size?
How does Soliris (Eculizumab) break out by Type, by Application?
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.In 2025, global Soliris (Eculizumab) production reached approximately 339 k units.The average gross profit margin of this product is 65%.
The core opportunity for Soliris lies in the expanding clinical value of complement biology across rare diseases, autoimmune disorders, neuroimmunology, and kidney diseases. As physicians gain a deeper understanding of complement-mediated mechanisms, high-risk patients once scattered across hematology, nephrology, neurology, and intensive care are being identified earlier, supporting the expansion of targeted complement therapy from classic rare indications into broader immune-inflammatory settings. Corporate annual reports and regulatory documents show that Soliris has become a key benchmark for the commercialization of complement inhibitors. Its value is not limited to product revenue, but also extends to rare disease care pathways, patient screening, long-term treatment management, and global market access capabilities. For CEOs, marketing leaders, and investors, eculizumab represents an innovative biologics segment where high barriers, strong clinical value, and substantial willingness to pay coexist.The main challenges come from reimbursement pressure, competitive innovation, biosimilar entry, and safety management. As a high-value rare disease therapy, Soliris faces commercial constraints related to treatment cost and reimbursement access. At the same time, long-acting C5 inhibitors, subcutaneous complement drugs, alternative pathway inhibitors, and biosimilars are reshaping the competitive landscape. Clinically, complement inhibition requires strict management of risks such as meningococcal infection, meaning patients often require vaccination, risk education, and continuous monitoring. Because the target diseases involve limited patient populations, complex diagnostic pathways, and high demand for multidisciplinary collaboration, companies must continue investing in medical education, patient identification, real-world evidence, and payer communication to sustain lifecycle value.Downstream demand is shifting from rescue treatment for critically ill patients toward early diagnosis, early treatment, and long-term disease control. Hematology, nephrology, neurology, pediatrics, rheumatology, immunology, and rare disease centers now evaluate eculizumab not only through efficacy, but also through patient stratification, disease progression management, quality-of-life improvement, and long-term safety. As rare disease networks, genetic testing, complement testing, and multidisciplinary consultation systems mature, more potential patients may enter standardized treatment pathways. At the same time, patients and payers are placing greater emphasis on dosing convenience, treatment continuity, real-world benefit, and total healthcare cost control, encouraging companies to build a more complete ecosystem around drugs, diagnostics, follow-up, patient support, and access solutions.
LP Information, Inc. (LPI) ' newest research report, the ?Soliris (Eculizumab) Industry Forecast? looks at past sales and reviews total world Soliris (Eculizumab) sales in 2025, providing a comprehensive analysis by region and market sector of projected Soliris (Eculizumab) sales for 2026 through 2032. With Soliris (Eculizumab) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Soliris (Eculizumab) industry.
This Insight Report provides a comprehensive analysis of the global Soliris (Eculizumab) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Soliris (Eculizumab) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Soliris (Eculizumab) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Soliris (Eculizumab) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Soliris (Eculizumab).
This report presents a comprehensive overview, market shares, and growth opportunities of Soliris (Eculizumab) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Plasma Exchange
- Plasma Infusion
- Paroxysmal Nocturnal Hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Other
- Pre-filled Injections
- Vials
- Hospital Infusion Therapy
- Long-term Maintenance Therapy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Alexion
- AstraZeneca
- Samsung Bioepis
- Amgen
- Epirus Biopharmaceuticals
What is the 10-year outlook for the global Soliris (Eculizumab) market?
What factors are driving Soliris (Eculizumab) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Soliris (Eculizumab) market opportunities vary by end market size?
How does Soliris (Eculizumab) break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Soliris (Eculizumab) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Soliris (Eculizumab) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Soliris (Eculizumab) by Country/Region, 2021, 2025 & 2032
2.2 Soliris (Eculizumab) Segment by Type
2.2.1 Plasma Exchange
2.2.2 Plasma Infusion
2.2.3 Soliris (Eculizumab) Sales by Type
2.2.3.1 Global Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
2.2.3.2 Global Soliris (Eculizumab) Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Soliris (Eculizumab) Sale Price by Type (2021-2026)
2.3 Soliris (Eculizumab) Segment by Complement Pathway Target
2.3.1 Paroxysmal Nocturnal Hemoglobinuria
2.3.2 Atypical Hemolytic Uremic Syndrome
2.3.3 Other
2.3.4 Soliris (Eculizumab) Sales by Complement Pathway Target
2.3.4.1 Global Soliris (Eculizumab) Sales Market Share by Complement Pathway Target (2021-2026)
2.3.4.2 Global Soliris (Eculizumab) Revenue and Market Share by Complement Pathway Target (2021-2026)
2.3.4.3 Global Soliris (Eculizumab) Sale Price by Complement Pathway Target (2021-2026)
2.4 Soliris (Eculizumab) Segment by Package
2.4.1 Pre-filled Injections
2.4.2 Vials
2.4.3 Soliris (Eculizumab) Sales by Package
2.4.3.1 Global Soliris (Eculizumab) Sales Market Share by Package (2021-2026)
2.4.3.2 Global Soliris (Eculizumab) Revenue and Market Share by Package (2021-2026)
2.4.3.3 Global Soliris (Eculizumab) Sale Price by Package (2021-2026)
2.5 Soliris (Eculizumab) Segment by Application
2.5.1 Hospital Infusion Therapy
2.5.2 Long-term Maintenance Therapy
2.5.3 Other
2.5.4 Soliris (Eculizumab) Sales by Application
2.5.4.1 Global Soliris (Eculizumab) Sale Market Share by Application (2021-2026)
2.5.4.2 Global Soliris (Eculizumab) Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Soliris (Eculizumab) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Soliris (Eculizumab) Breakdown Data by Company
3.1.1 Global Soliris (Eculizumab) Annual Sales by Company (2021-2026)
3.1.2 Global Soliris (Eculizumab) Sales Market Share by Company (2021-2026)
3.2 Global Soliris (Eculizumab) Annual Revenue by Company (2021-2026)
3.2.1 Global Soliris (Eculizumab) Revenue by Company (2021-2026)
3.2.2 Global Soliris (Eculizumab) Revenue Market Share by Company (2021-2026)
3.3 Global Soliris (Eculizumab) Sale Price by Company
3.4 Key Manufacturers Soliris (Eculizumab) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Soliris (Eculizumab) Product Location Distribution
3.4.2 Players Soliris (Eculizumab) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SOLIRIS (ECULIZUMAB) BY GEOGRAPHIC REGION
4.1 World Historic Soliris (Eculizumab) Market Size by Geographic Region (2021-2026)
4.1.1 Global Soliris (Eculizumab) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Soliris (Eculizumab) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Soliris (Eculizumab) Market Size by Country/Region (2021-2026)
4.2.1 Global Soliris (Eculizumab) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Soliris (Eculizumab) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Soliris (Eculizumab) Sales Growth
4.4 APAC Soliris (Eculizumab) Sales Growth
4.5 Europe Soliris (Eculizumab) Sales Growth
4.6 Middle East & Africa Soliris (Eculizumab) Sales Growth
5 AMERICAS
5.1 Americas Soliris (Eculizumab) Sales by Country
5.1.1 Americas Soliris (Eculizumab) Sales by Country (2021-2026)
5.1.2 Americas Soliris (Eculizumab) Revenue by Country (2021-2026)
5.2 Americas Soliris (Eculizumab) Sales by Type (2021-2026)
5.3 Americas Soliris (Eculizumab) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Soliris (Eculizumab) Sales by Region
6.1.1 APAC Soliris (Eculizumab) Sales by Region (2021-2026)
6.1.2 APAC Soliris (Eculizumab) Revenue by Region (2021-2026)
6.2 APAC Soliris (Eculizumab) Sales by Type (2021-2026)
6.3 APAC Soliris (Eculizumab) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Soliris (Eculizumab) by Country
7.1.1 Europe Soliris (Eculizumab) Sales by Country (2021-2026)
7.1.2 Europe Soliris (Eculizumab) Revenue by Country (2021-2026)
7.2 Europe Soliris (Eculizumab) Sales by Type (2021-2026)
7.3 Europe Soliris (Eculizumab) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Soliris (Eculizumab) by Country
8.1.1 Middle East & Africa Soliris (Eculizumab) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Soliris (Eculizumab) Revenue by Country (2021-2026)
8.2 Middle East & Africa Soliris (Eculizumab) Sales by Type (2021-2026)
8.3 Middle East & Africa Soliris (Eculizumab) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Soliris (Eculizumab)
10.3 Manufacturing Process Analysis of Soliris (Eculizumab)
10.4 Industry Chain Structure of Soliris (Eculizumab)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Soliris (Eculizumab) Distributors
11.3 Soliris (Eculizumab) Customer
12 WORLD FORECAST REVIEW FOR SOLIRIS (ECULIZUMAB) BY GEOGRAPHIC REGION
12.1 Global Soliris (Eculizumab) Market Size Forecast by Region
12.1.1 Global Soliris (Eculizumab) Forecast by Region (2027-2032)
12.1.2 Global Soliris (Eculizumab) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Soliris (Eculizumab) Forecast by Type (2027-2032)
12.7 Global Soliris (Eculizumab) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Alexion
13.1.1 Alexion Company Information
13.1.2 Alexion Soliris (Eculizumab) Product Portfolios and Specifications
13.1.3 Alexion Soliris (Eculizumab) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Alexion Main Business Overview
13.1.5 Alexion Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Soliris (Eculizumab) Product Portfolios and Specifications
13.2.3 AstraZeneca Soliris (Eculizumab) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Samsung Bioepis
13.3.1 Samsung Bioepis Company Information
13.3.2 Samsung Bioepis Soliris (Eculizumab) Product Portfolios and Specifications
13.3.3 Samsung Bioepis Soliris (Eculizumab) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Samsung Bioepis Main Business Overview
13.3.5 Samsung Bioepis Latest Developments
13.4 Amgen
13.4.1 Amgen Company Information
13.4.2 Amgen Soliris (Eculizumab) Product Portfolios and Specifications
13.4.3 Amgen Soliris (Eculizumab) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Amgen Main Business Overview
13.4.5 Amgen Latest Developments
13.5 Epirus Biopharmaceuticals
13.5.1 Epirus Biopharmaceuticals Company Information
13.5.2 Epirus Biopharmaceuticals Soliris (Eculizumab) Product Portfolios and Specifications
13.5.3 Epirus Biopharmaceuticals Soliris (Eculizumab) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Epirus Biopharmaceuticals Main Business Overview
13.5.5 Epirus Biopharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Soliris (Eculizumab) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Soliris (Eculizumab) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Soliris (Eculizumab) by Country/Region, 2021, 2025 & 2032
2.2 Soliris (Eculizumab) Segment by Type
2.2.1 Plasma Exchange
2.2.2 Plasma Infusion
2.2.3 Soliris (Eculizumab) Sales by Type
2.2.3.1 Global Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
2.2.3.2 Global Soliris (Eculizumab) Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Soliris (Eculizumab) Sale Price by Type (2021-2026)
2.3 Soliris (Eculizumab) Segment by Complement Pathway Target
2.3.1 Paroxysmal Nocturnal Hemoglobinuria
2.3.2 Atypical Hemolytic Uremic Syndrome
2.3.3 Other
2.3.4 Soliris (Eculizumab) Sales by Complement Pathway Target
2.3.4.1 Global Soliris (Eculizumab) Sales Market Share by Complement Pathway Target (2021-2026)
2.3.4.2 Global Soliris (Eculizumab) Revenue and Market Share by Complement Pathway Target (2021-2026)
2.3.4.3 Global Soliris (Eculizumab) Sale Price by Complement Pathway Target (2021-2026)
2.4 Soliris (Eculizumab) Segment by Package
2.4.1 Pre-filled Injections
2.4.2 Vials
2.4.3 Soliris (Eculizumab) Sales by Package
2.4.3.1 Global Soliris (Eculizumab) Sales Market Share by Package (2021-2026)
2.4.3.2 Global Soliris (Eculizumab) Revenue and Market Share by Package (2021-2026)
2.4.3.3 Global Soliris (Eculizumab) Sale Price by Package (2021-2026)
2.5 Soliris (Eculizumab) Segment by Application
2.5.1 Hospital Infusion Therapy
2.5.2 Long-term Maintenance Therapy
2.5.3 Other
2.5.4 Soliris (Eculizumab) Sales by Application
2.5.4.1 Global Soliris (Eculizumab) Sale Market Share by Application (2021-2026)
2.5.4.2 Global Soliris (Eculizumab) Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Soliris (Eculizumab) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Soliris (Eculizumab) Breakdown Data by Company
3.1.1 Global Soliris (Eculizumab) Annual Sales by Company (2021-2026)
3.1.2 Global Soliris (Eculizumab) Sales Market Share by Company (2021-2026)
3.2 Global Soliris (Eculizumab) Annual Revenue by Company (2021-2026)
3.2.1 Global Soliris (Eculizumab) Revenue by Company (2021-2026)
3.2.2 Global Soliris (Eculizumab) Revenue Market Share by Company (2021-2026)
3.3 Global Soliris (Eculizumab) Sale Price by Company
3.4 Key Manufacturers Soliris (Eculizumab) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Soliris (Eculizumab) Product Location Distribution
3.4.2 Players Soliris (Eculizumab) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SOLIRIS (ECULIZUMAB) BY GEOGRAPHIC REGION
4.1 World Historic Soliris (Eculizumab) Market Size by Geographic Region (2021-2026)
4.1.1 Global Soliris (Eculizumab) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Soliris (Eculizumab) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Soliris (Eculizumab) Market Size by Country/Region (2021-2026)
4.2.1 Global Soliris (Eculizumab) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Soliris (Eculizumab) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Soliris (Eculizumab) Sales Growth
4.4 APAC Soliris (Eculizumab) Sales Growth
4.5 Europe Soliris (Eculizumab) Sales Growth
4.6 Middle East & Africa Soliris (Eculizumab) Sales Growth
5 AMERICAS
5.1 Americas Soliris (Eculizumab) Sales by Country
5.1.1 Americas Soliris (Eculizumab) Sales by Country (2021-2026)
5.1.2 Americas Soliris (Eculizumab) Revenue by Country (2021-2026)
5.2 Americas Soliris (Eculizumab) Sales by Type (2021-2026)
5.3 Americas Soliris (Eculizumab) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Soliris (Eculizumab) Sales by Region
6.1.1 APAC Soliris (Eculizumab) Sales by Region (2021-2026)
6.1.2 APAC Soliris (Eculizumab) Revenue by Region (2021-2026)
6.2 APAC Soliris (Eculizumab) Sales by Type (2021-2026)
6.3 APAC Soliris (Eculizumab) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Soliris (Eculizumab) by Country
7.1.1 Europe Soliris (Eculizumab) Sales by Country (2021-2026)
7.1.2 Europe Soliris (Eculizumab) Revenue by Country (2021-2026)
7.2 Europe Soliris (Eculizumab) Sales by Type (2021-2026)
7.3 Europe Soliris (Eculizumab) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Soliris (Eculizumab) by Country
8.1.1 Middle East & Africa Soliris (Eculizumab) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Soliris (Eculizumab) Revenue by Country (2021-2026)
8.2 Middle East & Africa Soliris (Eculizumab) Sales by Type (2021-2026)
8.3 Middle East & Africa Soliris (Eculizumab) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Soliris (Eculizumab)
10.3 Manufacturing Process Analysis of Soliris (Eculizumab)
10.4 Industry Chain Structure of Soliris (Eculizumab)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Soliris (Eculizumab) Distributors
11.3 Soliris (Eculizumab) Customer
12 WORLD FORECAST REVIEW FOR SOLIRIS (ECULIZUMAB) BY GEOGRAPHIC REGION
12.1 Global Soliris (Eculizumab) Market Size Forecast by Region
12.1.1 Global Soliris (Eculizumab) Forecast by Region (2027-2032)
12.1.2 Global Soliris (Eculizumab) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Soliris (Eculizumab) Forecast by Type (2027-2032)
12.7 Global Soliris (Eculizumab) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Alexion
13.1.1 Alexion Company Information
13.1.2 Alexion Soliris (Eculizumab) Product Portfolios and Specifications
13.1.3 Alexion Soliris (Eculizumab) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Alexion Main Business Overview
13.1.5 Alexion Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Soliris (Eculizumab) Product Portfolios and Specifications
13.2.3 AstraZeneca Soliris (Eculizumab) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Samsung Bioepis
13.3.1 Samsung Bioepis Company Information
13.3.2 Samsung Bioepis Soliris (Eculizumab) Product Portfolios and Specifications
13.3.3 Samsung Bioepis Soliris (Eculizumab) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Samsung Bioepis Main Business Overview
13.3.5 Samsung Bioepis Latest Developments
13.4 Amgen
13.4.1 Amgen Company Information
13.4.2 Amgen Soliris (Eculizumab) Product Portfolios and Specifications
13.4.3 Amgen Soliris (Eculizumab) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Amgen Main Business Overview
13.4.5 Amgen Latest Developments
13.5 Epirus Biopharmaceuticals
13.5.1 Epirus Biopharmaceuticals Company Information
13.5.2 Epirus Biopharmaceuticals Soliris (Eculizumab) Product Portfolios and Specifications
13.5.3 Epirus Biopharmaceuticals Soliris (Eculizumab) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Epirus Biopharmaceuticals Main Business Overview
13.5.5 Epirus Biopharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Soliris (Eculizumab) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Soliris (Eculizumab) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Plasma Exchange
Table 4. Major Players of Plasma Infusion
Table 5. Global Soliris (Eculizumab) Sales by Type (2021-2026) & (K Units)
Table 6. Global Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
Table 7. Global Soliris (Eculizumab) Revenue by Type (2021-2026) & ($ million)
Table 8. Global Soliris (Eculizumab) Revenue Market Share by Type (2021-2026)
Table 9. Global Soliris (Eculizumab) Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Paroxysmal Nocturnal Hemoglobinuria
Table 11. Major Players of Atypical Hemolytic Uremic Syndrome
Table 12. Major Players of Other
Table 13. Global Soliris (Eculizumab) Sales by Complement Pathway Target (2021-2026) & (K Units)
Table 14. Global Soliris (Eculizumab) Sales Market Share by Complement Pathway Target (2021-2026)
Table 15. Global Soliris (Eculizumab) Revenue by Complement Pathway Target (2021-2026) & ($ million)
Table 16. Global Soliris (Eculizumab) Revenue Market Share by Complement Pathway Target (2021-2026)
Table 17. Global Soliris (Eculizumab) Sale Price by Complement Pathway Target (2021-2026) & (US$/Unit)
Table 18. Major Players of Pre-filled Injections
Table 19. Major Players of Vials
Table 20. Global Soliris (Eculizumab) Sales by Package (2021-2026) & (K Units)
Table 21. Global Soliris (Eculizumab) Sales Market Share by Package (2021-2026)
Table 22. Global Soliris (Eculizumab) Revenue by Package (2021-2026) & ($ million)
Table 23. Global Soliris (Eculizumab) Revenue Market Share by Package (2021-2026)
Table 24. Global Soliris (Eculizumab) Sale Price by Package (2021-2026) & (US$/Unit)
Table 25. Global Soliris (Eculizumab) Sale by Application (2021-2026) & (K Units)
Table 26. Global Soliris (Eculizumab) Sale Market Share by Application (2021-2026)
Table 27. Global Soliris (Eculizumab) Revenue by Application (2021-2026) & ($ million)
Table 28. Global Soliris (Eculizumab) Revenue Market Share by Application (2021-2026)
Table 29. Global Soliris (Eculizumab) Sale Price by Application (2021-2026) & (US$/Unit)
Table 30. Global Soliris (Eculizumab) Sales by Company (2021-2026) & (K Units)
Table 31. Global Soliris (Eculizumab) Sales Market Share by Company (2021-2026)
Table 32. Global Soliris (Eculizumab) Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Soliris (Eculizumab) Revenue Market Share by Company (2021-2026)
Table 34. Global Soliris (Eculizumab) Sale Price by Company (2021-2026) & (US$/Unit)
Table 35. Key Manufacturers Soliris (Eculizumab) Producing Area Distribution and Sales Area
Table 36. Players Soliris (Eculizumab) Products Offered
Table 37. Soliris (Eculizumab) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Soliris (Eculizumab) Sales by Geographic Region (2021-2026) & (K Units)
Table 41. Global Soliris (Eculizumab) Sales Market Share Geographic Region (2021-2026)
Table 42. Global Soliris (Eculizumab) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Soliris (Eculizumab) Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Soliris (Eculizumab) Sales by Country/Region (2021-2026) & (K Units)
Table 45. Global Soliris (Eculizumab) Sales Market Share by Country/Region (2021-2026)
Table 46. Global Soliris (Eculizumab) Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Soliris (Eculizumab) Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Soliris (Eculizumab) Sales by Country (2021-2026) & (K Units)
Table 49. Americas Soliris (Eculizumab) Sales Market Share by Country (2021-2026)
Table 50. Americas Soliris (Eculizumab) Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Soliris (Eculizumab) Sales by Type (2021-2026) & (K Units)
Table 52. Americas Soliris (Eculizumab) Sales by Application (2021-2026) & (K Units)
Table 53. APAC Soliris (Eculizumab) Sales by Region (2021-2026) & (K Units)
Table 54. APAC Soliris (Eculizumab) Sales Market Share by Region (2021-2026)
Table 55. APAC Soliris (Eculizumab) Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Soliris (Eculizumab) Sales by Type (2021-2026) & (K Units)
Table 57. APAC Soliris (Eculizumab) Sales by Application (2021-2026) & (K Units)
Table 58. Europe Soliris (Eculizumab) Sales by Country (2021-2026) & (K Units)
Table 59. Europe Soliris (Eculizumab) Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Soliris (Eculizumab) Sales by Type (2021-2026) & (K Units)
Table 61. Europe Soliris (Eculizumab) Sales by Application (2021-2026) & (K Units)
Table 62. Middle East & Africa Soliris (Eculizumab) Sales by Country (2021-2026) & (K Units)
Table 63. Middle East & Africa Soliris (Eculizumab) Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Soliris (Eculizumab) Sales by Type (2021-2026) & (K Units)
Table 65. Middle East & Africa Soliris (Eculizumab) Sales by Application (2021-2026) & (K Units)
Table 66. Key Market Drivers & Growth Opportunities of Soliris (Eculizumab)
Table 67. Key Market Challenges & Risks of Soliris (Eculizumab)
Table 68. Key Industry Trends of Soliris (Eculizumab)
Table 69. Soliris (Eculizumab) Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Soliris (Eculizumab) Distributors List
Table 72. Soliris (Eculizumab) Customer List
Table 73. Global Soliris (Eculizumab) Sales Forecast by Region (2027-2032) & (K Units)
Table 74. Global Soliris (Eculizumab) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Soliris (Eculizumab) Sales Forecast by Country (2027-2032) & (K Units)
Table 76. Americas Soliris (Eculizumab) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Soliris (Eculizumab) Sales Forecast by Region (2027-2032) & (K Units)
Table 78. APAC Soliris (Eculizumab) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Soliris (Eculizumab) Sales Forecast by Country (2027-2032) & (K Units)
Table 80. Europe Soliris (Eculizumab) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Soliris (Eculizumab) Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Middle East & Africa Soliris (Eculizumab) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Soliris (Eculizumab) Sales Forecast by Type (2027-2032) & (K Units)
Table 84. Global Soliris (Eculizumab) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Soliris (Eculizumab) Sales Forecast by Application (2027-2032) & (K Units)
Table 86. Global Soliris (Eculizumab) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. Alexion Basic Information, Soliris (Eculizumab) Manufacturing Base, Sales Area and Its Competitors
Table 88. Alexion Soliris (Eculizumab) Product Portfolios and Specifications
Table 89. Alexion Soliris (Eculizumab) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Alexion Main Business
Table 91. Alexion Latest Developments
Table 92. AstraZeneca Basic Information, Soliris (Eculizumab) Manufacturing Base, Sales Area and Its Competitors
Table 93. AstraZeneca Soliris (Eculizumab) Product Portfolios and Specifications
Table 94. AstraZeneca Soliris (Eculizumab) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. AstraZeneca Main Business
Table 96. AstraZeneca Latest Developments
Table 97. Samsung Bioepis Basic Information, Soliris (Eculizumab) Manufacturing Base, Sales Area and Its Competitors
Table 98. Samsung Bioepis Soliris (Eculizumab) Product Portfolios and Specifications
Table 99. Samsung Bioepis Soliris (Eculizumab) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Samsung Bioepis Main Business
Table 101. Samsung Bioepis Latest Developments
Table 102. Amgen Basic Information, Soliris (Eculizumab) Manufacturing Base, Sales Area and Its Competitors
Table 103. Amgen Soliris (Eculizumab) Product Portfolios and Specifications
Table 104. Amgen Soliris (Eculizumab) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Amgen Main Business
Table 106. Amgen Latest Developments
Table 107. Epirus Biopharmaceuticals Basic Information, Soliris (Eculizumab) Manufacturing Base, Sales Area and Its Competitors
Table 108. Epirus Biopharmaceuticals Soliris (Eculizumab) Product Portfolios and Specifications
Table 109. Epirus Biopharmaceuticals Soliris (Eculizumab) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Epirus Biopharmaceuticals Main Business
Table 111. Epirus Biopharmaceuticals Latest Developments
Table 1. Soliris (Eculizumab) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Soliris (Eculizumab) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Plasma Exchange
Table 4. Major Players of Plasma Infusion
Table 5. Global Soliris (Eculizumab) Sales by Type (2021-2026) & (K Units)
Table 6. Global Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
Table 7. Global Soliris (Eculizumab) Revenue by Type (2021-2026) & ($ million)
Table 8. Global Soliris (Eculizumab) Revenue Market Share by Type (2021-2026)
Table 9. Global Soliris (Eculizumab) Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Paroxysmal Nocturnal Hemoglobinuria
Table 11. Major Players of Atypical Hemolytic Uremic Syndrome
Table 12. Major Players of Other
Table 13. Global Soliris (Eculizumab) Sales by Complement Pathway Target (2021-2026) & (K Units)
Table 14. Global Soliris (Eculizumab) Sales Market Share by Complement Pathway Target (2021-2026)
Table 15. Global Soliris (Eculizumab) Revenue by Complement Pathway Target (2021-2026) & ($ million)
Table 16. Global Soliris (Eculizumab) Revenue Market Share by Complement Pathway Target (2021-2026)
Table 17. Global Soliris (Eculizumab) Sale Price by Complement Pathway Target (2021-2026) & (US$/Unit)
Table 18. Major Players of Pre-filled Injections
Table 19. Major Players of Vials
Table 20. Global Soliris (Eculizumab) Sales by Package (2021-2026) & (K Units)
Table 21. Global Soliris (Eculizumab) Sales Market Share by Package (2021-2026)
Table 22. Global Soliris (Eculizumab) Revenue by Package (2021-2026) & ($ million)
Table 23. Global Soliris (Eculizumab) Revenue Market Share by Package (2021-2026)
Table 24. Global Soliris (Eculizumab) Sale Price by Package (2021-2026) & (US$/Unit)
Table 25. Global Soliris (Eculizumab) Sale by Application (2021-2026) & (K Units)
Table 26. Global Soliris (Eculizumab) Sale Market Share by Application (2021-2026)
Table 27. Global Soliris (Eculizumab) Revenue by Application (2021-2026) & ($ million)
Table 28. Global Soliris (Eculizumab) Revenue Market Share by Application (2021-2026)
Table 29. Global Soliris (Eculizumab) Sale Price by Application (2021-2026) & (US$/Unit)
Table 30. Global Soliris (Eculizumab) Sales by Company (2021-2026) & (K Units)
Table 31. Global Soliris (Eculizumab) Sales Market Share by Company (2021-2026)
Table 32. Global Soliris (Eculizumab) Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Soliris (Eculizumab) Revenue Market Share by Company (2021-2026)
Table 34. Global Soliris (Eculizumab) Sale Price by Company (2021-2026) & (US$/Unit)
Table 35. Key Manufacturers Soliris (Eculizumab) Producing Area Distribution and Sales Area
Table 36. Players Soliris (Eculizumab) Products Offered
Table 37. Soliris (Eculizumab) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Soliris (Eculizumab) Sales by Geographic Region (2021-2026) & (K Units)
Table 41. Global Soliris (Eculizumab) Sales Market Share Geographic Region (2021-2026)
Table 42. Global Soliris (Eculizumab) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Soliris (Eculizumab) Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Soliris (Eculizumab) Sales by Country/Region (2021-2026) & (K Units)
Table 45. Global Soliris (Eculizumab) Sales Market Share by Country/Region (2021-2026)
Table 46. Global Soliris (Eculizumab) Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Soliris (Eculizumab) Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Soliris (Eculizumab) Sales by Country (2021-2026) & (K Units)
Table 49. Americas Soliris (Eculizumab) Sales Market Share by Country (2021-2026)
Table 50. Americas Soliris (Eculizumab) Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Soliris (Eculizumab) Sales by Type (2021-2026) & (K Units)
Table 52. Americas Soliris (Eculizumab) Sales by Application (2021-2026) & (K Units)
Table 53. APAC Soliris (Eculizumab) Sales by Region (2021-2026) & (K Units)
Table 54. APAC Soliris (Eculizumab) Sales Market Share by Region (2021-2026)
Table 55. APAC Soliris (Eculizumab) Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Soliris (Eculizumab) Sales by Type (2021-2026) & (K Units)
Table 57. APAC Soliris (Eculizumab) Sales by Application (2021-2026) & (K Units)
Table 58. Europe Soliris (Eculizumab) Sales by Country (2021-2026) & (K Units)
Table 59. Europe Soliris (Eculizumab) Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Soliris (Eculizumab) Sales by Type (2021-2026) & (K Units)
Table 61. Europe Soliris (Eculizumab) Sales by Application (2021-2026) & (K Units)
Table 62. Middle East & Africa Soliris (Eculizumab) Sales by Country (2021-2026) & (K Units)
Table 63. Middle East & Africa Soliris (Eculizumab) Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Soliris (Eculizumab) Sales by Type (2021-2026) & (K Units)
Table 65. Middle East & Africa Soliris (Eculizumab) Sales by Application (2021-2026) & (K Units)
Table 66. Key Market Drivers & Growth Opportunities of Soliris (Eculizumab)
Table 67. Key Market Challenges & Risks of Soliris (Eculizumab)
Table 68. Key Industry Trends of Soliris (Eculizumab)
Table 69. Soliris (Eculizumab) Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Soliris (Eculizumab) Distributors List
Table 72. Soliris (Eculizumab) Customer List
Table 73. Global Soliris (Eculizumab) Sales Forecast by Region (2027-2032) & (K Units)
Table 74. Global Soliris (Eculizumab) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Soliris (Eculizumab) Sales Forecast by Country (2027-2032) & (K Units)
Table 76. Americas Soliris (Eculizumab) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Soliris (Eculizumab) Sales Forecast by Region (2027-2032) & (K Units)
Table 78. APAC Soliris (Eculizumab) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Soliris (Eculizumab) Sales Forecast by Country (2027-2032) & (K Units)
Table 80. Europe Soliris (Eculizumab) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Soliris (Eculizumab) Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Middle East & Africa Soliris (Eculizumab) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Soliris (Eculizumab) Sales Forecast by Type (2027-2032) & (K Units)
Table 84. Global Soliris (Eculizumab) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Soliris (Eculizumab) Sales Forecast by Application (2027-2032) & (K Units)
Table 86. Global Soliris (Eculizumab) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. Alexion Basic Information, Soliris (Eculizumab) Manufacturing Base, Sales Area and Its Competitors
Table 88. Alexion Soliris (Eculizumab) Product Portfolios and Specifications
Table 89. Alexion Soliris (Eculizumab) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Alexion Main Business
Table 91. Alexion Latest Developments
Table 92. AstraZeneca Basic Information, Soliris (Eculizumab) Manufacturing Base, Sales Area and Its Competitors
Table 93. AstraZeneca Soliris (Eculizumab) Product Portfolios and Specifications
Table 94. AstraZeneca Soliris (Eculizumab) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. AstraZeneca Main Business
Table 96. AstraZeneca Latest Developments
Table 97. Samsung Bioepis Basic Information, Soliris (Eculizumab) Manufacturing Base, Sales Area and Its Competitors
Table 98. Samsung Bioepis Soliris (Eculizumab) Product Portfolios and Specifications
Table 99. Samsung Bioepis Soliris (Eculizumab) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Samsung Bioepis Main Business
Table 101. Samsung Bioepis Latest Developments
Table 102. Amgen Basic Information, Soliris (Eculizumab) Manufacturing Base, Sales Area and Its Competitors
Table 103. Amgen Soliris (Eculizumab) Product Portfolios and Specifications
Table 104. Amgen Soliris (Eculizumab) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Amgen Main Business
Table 106. Amgen Latest Developments
Table 107. Epirus Biopharmaceuticals Basic Information, Soliris (Eculizumab) Manufacturing Base, Sales Area and Its Competitors
Table 108. Epirus Biopharmaceuticals Soliris (Eculizumab) Product Portfolios and Specifications
Table 109. Epirus Biopharmaceuticals Soliris (Eculizumab) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Epirus Biopharmaceuticals Main Business
Table 111. Epirus Biopharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Soliris (Eculizumab)
Figure 2. Soliris (Eculizumab) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Soliris (Eculizumab) Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Soliris (Eculizumab) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Soliris (Eculizumab) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Soliris (Eculizumab) Sales Market Share by Country/Region (2025)
Figure 10. Soliris (Eculizumab) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Plasma Exchange
Figure 12. Product Picture of Plasma Infusion
Figure 13. Global Soliris (Eculizumab) Sales Market Share by Type in 2026
Figure 14. Global Soliris (Eculizumab) Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Paroxysmal Nocturnal Hemoglobinuria
Figure 16. Product Picture of Atypical Hemolytic Uremic Syndrome
Figure 17. Product Picture of Other
Figure 18. Global Soliris (Eculizumab) Sales Market Share by Complement Pathway Target in 2026
Figure 19. Global Soliris (Eculizumab) Revenue Market Share by Complement Pathway Target (2021-2026)
Figure 20. Product Picture of Pre-filled Injections
Figure 21. Product Picture of Vials
Figure 22. Global Soliris (Eculizumab) Sales Market Share by Package in 2026
Figure 23. Global Soliris (Eculizumab) Revenue Market Share by Package (2021-2026)
Figure 24. Soliris (Eculizumab) Consumed in Hospital Infusion Therapy
Figure 25. Global Soliris (Eculizumab) Market: Hospital Infusion Therapy (2021-2026) & (K Units)
Figure 26. Soliris (Eculizumab) Consumed in Long-term Maintenance Therapy
Figure 27. Global Soliris (Eculizumab) Market: Long-term Maintenance Therapy (2021-2026) & (K Units)
Figure 28. Soliris (Eculizumab) Consumed in Other
Figure 29. Global Soliris (Eculizumab) Market: Other (2021-2026) & (K Units)
Figure 30. Global Soliris (Eculizumab) Sale Market Share by Application (2025)
Figure 31. Global Soliris (Eculizumab) Revenue Market Share by Application in 2025
Figure 32. Soliris (Eculizumab) Sales by Company in 2025 (K Units)
Figure 33. Global Soliris (Eculizumab) Sales Market Share by Company in 2025
Figure 34. Soliris (Eculizumab) Revenue by Company in 2025 ($ millions)
Figure 35. Global Soliris (Eculizumab) Revenue Market Share by Company in 2025
Figure 36. Global Soliris (Eculizumab) Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Soliris (Eculizumab) Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Soliris (Eculizumab) Sales 2021-2026 (K Units)
Figure 39. Americas Soliris (Eculizumab) Revenue 2021-2026 ($ millions)
Figure 40. APAC Soliris (Eculizumab) Sales 2021-2026 (K Units)
Figure 41. APAC Soliris (Eculizumab) Revenue 2021-2026 ($ millions)
Figure 42. Europe Soliris (Eculizumab) Sales 2021-2026 (K Units)
Figure 43. Europe Soliris (Eculizumab) Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Soliris (Eculizumab) Sales 2021-2026 (K Units)
Figure 45. Middle East & Africa Soliris (Eculizumab) Revenue 2021-2026 ($ millions)
Figure 46. Americas Soliris (Eculizumab) Sales Market Share by Country in 2025
Figure 47. Americas Soliris (Eculizumab) Revenue Market Share by Country (2021-2026)
Figure 48. Americas Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
Figure 49. Americas Soliris (Eculizumab) Sales Market Share by Application (2021-2026)
Figure 50. United States Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Soliris (Eculizumab) Sales Market Share by Region in 2025
Figure 55. APAC Soliris (Eculizumab) Revenue Market Share by Region (2021-2026)
Figure 56. APAC Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
Figure 57. APAC Soliris (Eculizumab) Sales Market Share by Application (2021-2026)
Figure 58. China Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 62. India Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Soliris (Eculizumab) Sales Market Share by Country in 2025
Figure 66. Europe Soliris (Eculizumab) Revenue Market Share by Country (2021-2026)
Figure 67. Europe Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
Figure 68. Europe Soliris (Eculizumab) Sales Market Share by Application (2021-2026)
Figure 69. Germany Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 70. France Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Soliris (Eculizumab) Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Soliris (Eculizumab) Sales Market Share by Application (2021-2026)
Figure 77. Egypt Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Soliris (Eculizumab) in 2026
Figure 83. Manufacturing Process Analysis of Soliris (Eculizumab)
Figure 84. Industry Chain Structure of Soliris (Eculizumab)
Figure 85. Channels of Distribution
Figure 86. Global Soliris (Eculizumab) Sales Market Forecast by Region (2027-2032)
Figure 87. Global Soliris (Eculizumab) Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Soliris (Eculizumab) Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Soliris (Eculizumab) Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Soliris (Eculizumab) Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Soliris (Eculizumab) Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Soliris (Eculizumab)
Figure 2. Soliris (Eculizumab) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Soliris (Eculizumab) Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Soliris (Eculizumab) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Soliris (Eculizumab) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Soliris (Eculizumab) Sales Market Share by Country/Region (2025)
Figure 10. Soliris (Eculizumab) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Plasma Exchange
Figure 12. Product Picture of Plasma Infusion
Figure 13. Global Soliris (Eculizumab) Sales Market Share by Type in 2026
Figure 14. Global Soliris (Eculizumab) Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Paroxysmal Nocturnal Hemoglobinuria
Figure 16. Product Picture of Atypical Hemolytic Uremic Syndrome
Figure 17. Product Picture of Other
Figure 18. Global Soliris (Eculizumab) Sales Market Share by Complement Pathway Target in 2026
Figure 19. Global Soliris (Eculizumab) Revenue Market Share by Complement Pathway Target (2021-2026)
Figure 20. Product Picture of Pre-filled Injections
Figure 21. Product Picture of Vials
Figure 22. Global Soliris (Eculizumab) Sales Market Share by Package in 2026
Figure 23. Global Soliris (Eculizumab) Revenue Market Share by Package (2021-2026)
Figure 24. Soliris (Eculizumab) Consumed in Hospital Infusion Therapy
Figure 25. Global Soliris (Eculizumab) Market: Hospital Infusion Therapy (2021-2026) & (K Units)
Figure 26. Soliris (Eculizumab) Consumed in Long-term Maintenance Therapy
Figure 27. Global Soliris (Eculizumab) Market: Long-term Maintenance Therapy (2021-2026) & (K Units)
Figure 28. Soliris (Eculizumab) Consumed in Other
Figure 29. Global Soliris (Eculizumab) Market: Other (2021-2026) & (K Units)
Figure 30. Global Soliris (Eculizumab) Sale Market Share by Application (2025)
Figure 31. Global Soliris (Eculizumab) Revenue Market Share by Application in 2025
Figure 32. Soliris (Eculizumab) Sales by Company in 2025 (K Units)
Figure 33. Global Soliris (Eculizumab) Sales Market Share by Company in 2025
Figure 34. Soliris (Eculizumab) Revenue by Company in 2025 ($ millions)
Figure 35. Global Soliris (Eculizumab) Revenue Market Share by Company in 2025
Figure 36. Global Soliris (Eculizumab) Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Soliris (Eculizumab) Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Soliris (Eculizumab) Sales 2021-2026 (K Units)
Figure 39. Americas Soliris (Eculizumab) Revenue 2021-2026 ($ millions)
Figure 40. APAC Soliris (Eculizumab) Sales 2021-2026 (K Units)
Figure 41. APAC Soliris (Eculizumab) Revenue 2021-2026 ($ millions)
Figure 42. Europe Soliris (Eculizumab) Sales 2021-2026 (K Units)
Figure 43. Europe Soliris (Eculizumab) Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Soliris (Eculizumab) Sales 2021-2026 (K Units)
Figure 45. Middle East & Africa Soliris (Eculizumab) Revenue 2021-2026 ($ millions)
Figure 46. Americas Soliris (Eculizumab) Sales Market Share by Country in 2025
Figure 47. Americas Soliris (Eculizumab) Revenue Market Share by Country (2021-2026)
Figure 48. Americas Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
Figure 49. Americas Soliris (Eculizumab) Sales Market Share by Application (2021-2026)
Figure 50. United States Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Soliris (Eculizumab) Sales Market Share by Region in 2025
Figure 55. APAC Soliris (Eculizumab) Revenue Market Share by Region (2021-2026)
Figure 56. APAC Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
Figure 57. APAC Soliris (Eculizumab) Sales Market Share by Application (2021-2026)
Figure 58. China Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 62. India Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Soliris (Eculizumab) Sales Market Share by Country in 2025
Figure 66. Europe Soliris (Eculizumab) Revenue Market Share by Country (2021-2026)
Figure 67. Europe Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
Figure 68. Europe Soliris (Eculizumab) Sales Market Share by Application (2021-2026)
Figure 69. Germany Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 70. France Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Soliris (Eculizumab) Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Soliris (Eculizumab) Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Soliris (Eculizumab) Sales Market Share by Application (2021-2026)
Figure 77. Egypt Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Soliris (Eculizumab) Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Soliris (Eculizumab) in 2026
Figure 83. Manufacturing Process Analysis of Soliris (Eculizumab)
Figure 84. Industry Chain Structure of Soliris (Eculizumab)
Figure 85. Channels of Distribution
Figure 86. Global Soliris (Eculizumab) Sales Market Forecast by Region (2027-2032)
Figure 87. Global Soliris (Eculizumab) Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Soliris (Eculizumab) Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Soliris (Eculizumab) Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Soliris (Eculizumab) Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Soliris (Eculizumab) Revenue Market Share Forecast by Application (2027-2032)
